bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Positive People Who Inject Drugs
Conditions
HIV Positive People Who Inject Drugs
Trial Timeline
Dec 22, 2021 → Dec 9, 2024
NCT ID
NCT07004933About bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) is a pre-clinical stage product being developed by Gilead Sciences for HIV Positive People Who Inject Drugs. The current trial status is completed. This product is registered under clinical trial identifier NCT07004933. Target conditions include HIV Positive People Who Inject Drugs.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07004933 | Pre-clinical | Completed |
Competing Products
20 competing products in HIV Positive People Who Inject Drugs